Pro Medicus' Busiest Year for Implementations Provides 'Strong Momentum' Heading Into Fiscal 2027, Jefferies Says

MT Newswires Live

08/18

Pro Medicus (ASX:PME) saw six major renewals in fiscal 2026 amid its busiest year for implementations, with many of them occurring late in the second half of the year, giving the company "strong momentum" heading into fiscal 2027, Jefferies said in a Tuesday note.

While the implementations did not contribute materially to fiscal 2026 revenue, Pro Medicus said they will provide a considerable step-up in transaction revenue in fiscal 2027 as the company will receive a full 12 months of revenue from the contracts.

The company reported fiscal 2026 normalized EPS of AU$1.39, up around 25% from a year earlier and ahead of Jefferies' estimate of AU$1.37.

The investment firm maintained a hold rating on Pro Medicus with a price target of AU$188.25.

Pro Medicus shares surged 13% in recent Tuesday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2660456028"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660456028\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660456028?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 11:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660456028","market":"us","top_or_hot":-1,"title":"Pro Medicus' Busiest Year for Implementations Provides 'Strong Momentum' Heading Into Fiscal 2027, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> (ASX:PME) saw six major renewals in fiscal 2026 amid its busiest year for implementations, with many of them occurring late in the second half of the year, giving the company \"strong momentum\" heading into fiscal 2027, Jefferies said in a Tuesday note.</p><p>While the implementations did not contribute materially to fiscal 2026 revenue, <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> said they will provide a considerable step-up in transaction revenue in fiscal 2027 as the company will receive a full 12 months of revenue from the contracts.</p><p>The company reported fiscal 2026 normalized EPS of AU$1.39, up around 25% from a year earlier and ahead of Jefferies' estimate of AU$1.37.</p><p>The investment firm maintained a hold rating on <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> with a price target of AU$188.25.</p><p>Pro Medicus shares surged 13% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus' Busiest Year for Implementations Provides 'Strong Momentum' Heading Into Fiscal 2027, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus' Busiest Year for Implementations Provides 'Strong Momentum' Heading Into Fiscal 2027, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-18 11:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> (ASX:PME) saw six major renewals in fiscal 2026 amid its busiest year for implementations, with many of them occurring late in the second half of the year, giving the company \"strong momentum\" heading into fiscal 2027, Jefferies said in a Tuesday note.</p><p>While the implementations did not contribute materially to fiscal 2026 revenue, <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> said they will provide a considerable step-up in transaction revenue in fiscal 2027 as the company will receive a full 12 months of revenue from the contracts.</p><p>The company reported fiscal 2026 normalized EPS of AU$1.39, up around 25% from a year earlier and ahead of Jefferies' estimate of AU$1.37.</p><p>The investment firm maintained a hold rating on <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> with a price target of AU$188.25.</p><p>Pro Medicus shares surged 13% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PME.AU","symbol_name":"PRO MEDICUS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660456028","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660456028","pubTimestamp":1787022304,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pro Medicus  saw six major renewals in fiscal 2026 amid its busiest year for implementations, with many of them occurring late in the second half of the year, giving the company \"strong momentum\" heading into fiscal 2027, Jefferies said in a Tuesday note.While the implementations did not contribute materially to fiscal 2026 revenue, Pro Medicus said they will provide a considerable step-up in transaction revenue in fiscal 2027 as the company will receive a full 12 months of revenue from the contracts.The company reported fiscal 2026 normalized EPS of AU$1.39, up around 25% from a year earlier and ahead of Jefferies' estimate of AU$1.37.The investment firm maintained a hold rating on Pro Medicus with a price target of AU$188.25.Pro Medicus shares surged 13% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术"},"translate_title":"杰富瑞表示，Pro Medicus 实施最繁忙的一年为 2027 财年提供了“强劲动力”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":1},"content_text":"Pro Medicus (ASX:PME) saw six major renewals in fiscal 2026 amid its busiest year for implementations, with many of them occurring late in the second half of the year, giving the company \"strong momentum\" heading into fiscal 2027, Jefferies said in a Tuesday note.While the implementations did not contribute materially to fiscal 2026 revenue, Pro Medicus said they will provide a considerable step-up in transaction revenue in fiscal 2027 as the company will receive a full 12 months of revenue from the contracts.The company reported fiscal 2026 normalized EPS of AU$1.39, up around 25% from a year earlier and ahead of Jefferies' estimate of AU$1.37.The investment firm maintained a hold rating on Pro Medicus with a price target of AU$188.25.Pro Medicus shares surged 13% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}